Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.53 |
| ▸ | PKM | P14618 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699995 | 1.00 | MAPT (0.53) | MAPTPKMPOLBSMN1; SMN2TDP1 | |
| SCHEMBL29034670 | 0.94 | MAPT (0.52) | MAPTPKMPOLBSMN1; SMN2TDP1 | |
| SCHEMBL16038895 | 0.90 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2TDP1 | |
| SCHEMBL28440217 | 0.89 | MAPT (0.51) | MAPTPKMPOLBSMN1; SMN2TDP1 | |
| SCHEMBL1700332 | 0.87 | MAPT (0.54) | MAPTPKMPOLBSMN1; SMN2TDP1 | |
| SCHEMBL19939708 | 0.87 | MAPT (0.45) | MAPTPKMPOLBSMN1; SMN2TDP1 | |
| SCHEMBL29589101 | 0.86 | MAPT (0.53) | MAPTPKMPOLBSMN1; SMN2TDP1 | |
| SCHEMBL16037480 | 0.86 | MAPT (0.56) | MAPTPKMPOLBSMN1; SMN2TDP1 | |
| SCHEMBL16039835 | 0.86 | MAPT (0.53) | MAPTPKMPOLBSMN1; SMN2TDP1 | |
| Hydrochloric Acid SCHEMBL22581377 | 0.85 | MAPT (0.52) | MAPTPKMPOLBSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217566-B | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-114929689-B | Bcl-2 inhibitors | 百济神州有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118084904-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-111801327-B | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116621860-A | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-116217566-A | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-111511748-B | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
| EP-4110298-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-115484933-A | Hot melt extrusion solid dispersions containing BCL2 inhibitors | 广州麓鹏制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-4051676-A1 | BCL-2 INHIBITORS | BeiGene, Ltd. (KY) | 2022-09-07 | — | — | EP | disclosed |
| US-11420968-B2 | Bcl-2 inhibitors | BEIGENE, LTD. (KY) | 2022-08-23 | — | — | US | disclosed |
| CN-111747949-B | Bcl-2 selective inhibitors | 首药控股(北京)股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022140224-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114126616-A | Nanoparticle formulations of BCL-2 inhibitors | 里科瑞尔姆IP控股有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420968-B2 | Bcl-2 inhibitors | BCL2, BCL2L1, BCL2L2 | MAPT 2900/4885PKM 4250/4885POLB 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.